Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHUK | O15111 | 11/20 | 0.42 |
| ▸ | MAP3K14 | Q99558 | 5/20 | 0.33 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19629513 | 0.90 | CHUK (0.39) | CHUKMAP3K14TTBK1CA12CA1 | |
| SCHEMBL19626289 | 0.89 | CHUK (0.41) | CHUKMAP3K14TTBK1CA12CA1 | |
| SCHEMBL20193230 | 0.85 | CHUK (0.61) | CHUKMAP3K14 | |
| SCHEMBL19629478 | 0.84 | CHUK (0.43) | CHUKMAP3K14NR3C1PGRNR3C2 | |
| SCHEMBL19629501 | 0.81 | LMNA (0.41) | CA12CA1CA2CA9 | |
| SCHEMBL19626286 | 0.79 | CHUK (0.38) | CHUKMAP3K14TTBK1CA12CA1 | |
| SCHEMBL19629428 | 0.78 | CHUK (0.43) | CHUKMAP3K14 | |
| SCHEMBL19629495 | 0.77 | CHUK (0.35) | CHUK | |
| SCHEMBL19629492 | 0.77 | CHUK (0.45) | CHUKMAP3K14TTBK1 | |
| SCHEMBL19629491 | 0.76 | CHUK (0.47) | CHUKMAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981962-B2 | Pyrazole derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K21 | CHUK 32/4885MAP3K14 1/4885TTBK1 713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.